A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-01

Study Completion Date

2023-10-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a first time in human study designed to assess the safety, tolerability, pharmacokinetics and PD of GSK3888130B over a range of dose levels in healthy participants.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686

NCT00721812

Inflammatory Bowel Diseases

COMPLETED PHASE1

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants

NCT04138043

Healthy Volunteers

COMPLETED PHASE1

Phase I Study of GSK2982772 in Japanese Healthy Male Participants

NCT03590613

Autoimmune Diseases

COMPLETED PHASE1

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

NCT02099201

Healthy Subjects

COMPLETED PHASE1

First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.

NCT00849134

Pain, Inflammatory

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis Colitis, Ulcerative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Participants will be randomized to receive either GSK3888130B or placebo in single ascending dose cohorts.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

This will be a double-blind study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1: Participants receiving GSK3888130B at dose level 1

Group Type EXPERIMENTAL

GSK3888130B

Intervention Type DRUG

GSK3888130B will be administered.

Cohort 1: Participants receiving placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered.

Cohort 2: Participants receiving GSK3888130B at dose level 2

Group Type EXPERIMENTAL

GSK3888130B

Intervention Type DRUG

GSK3888130B will be administered.

Cohort 2: Participants receiving placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered.

Cohort 3: Participants receiving GSK3888130B at dose level 3

Group Type EXPERIMENTAL

GSK3888130B

Intervention Type DRUG

GSK3888130B will be administered.

Cohort 3: Participants receiving placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered.

Cohort 4: Participants receiving GSK3888130B at dose level 4

Group Type EXPERIMENTAL

GSK3888130B

Intervention Type DRUG

GSK3888130B will be administered.

Cohort 4: Participants receiving placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered.

Cohort 5: Participants receiving GSK3888130B at dose level 5

Group Type EXPERIMENTAL

GSK3888130B

Intervention Type DRUG

GSK3888130B will be administered.

Cohort 5: Participants receiving placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered.

Cohort 6: Participants receiving GSK3888130B at dose level 6

Group Type EXPERIMENTAL

GSK3888130B

Intervention Type DRUG

GSK3888130B will be administered.

Cohort 6: Participants receiving placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered.

Cohort 7: Participants receiving GSK3888130B at dose level 7

Group Type EXPERIMENTAL

GSK3888130B

Intervention Type DRUG

GSK3888130B will be administered.

Cohort 7: Participants receiving placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GSK3888130B

GSK3888130B will be administered.

Intervention Type DRUG

Placebo

Placebo will be administered.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant must be 18 to 55 years of age inclusive.
* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
* Participants with a confirmed positive vaccination status for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines administered at least 30 days prior to dosing in the study.
* SARS-CoV-2 screening test negative as per local guidance.
* Participants with history of current/seasonal vaccination status for influenza or who consent to receive influenza vaccine at least 30 days prior to dosing, if study dosing is during influenza season (1st October to 30th April).
* Body weight greater than or equal to (\>=) 50 kilograms (kg) and body mass index (BMI) within the range 19.5-32 kilograms per square meter (kg/m\^2) (inclusive).
* Male and/or female of non-childbearing potential
* Capable of giving signed informed consent.

Exclusion Criteria

* Prior medical history of anaphylaxis.
* Immunodeficiency or autoimmunity assessed by medical history.
* A history of recurrent infections.
* Treatment of a chronic infection within 3 months prior to the first dose of study drug.
* Any acute infection (including upper respiratory tract infections and urinary tract infections) which has not fully resolved within four weeks of dosing
* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy.
* Current or chronic history of liver disease or known hepatic or biliary abnormalities.
* Participants with a history of renal disease or renal abnormalities.
* A clinically significant abnormality in the 12-lead ECG performed at screening.
* A clinically significant abnormality in the Holter monitor performed at screening.
* History of malignancy, including malignant or non-malignant skin cancer.
* Participants with known SARS-CoV-2 positive contacts in the past 14 days.
* Prior moderate/severe SARS-CoV-2 infection requiring oxygen supplementation or admission to hospital.
* Antibiotics or antiviral therapy within 30 days of dosing.
* Receipt of live vaccination within 30 days of dosing or plan to receive live vaccination during the study.
* Use of prescription drugs or non-prescription drugs, including non-steroidal anti inflammatory drug (NSAIDs), within 7 days prior to dosing, if in the opinion of the Investigator (in consultation with the GlaxoSmithKline \[GSK\] Medical Monitor if required) the medication will interfere with the study procedures or compromise participant safety.
* The participant has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
* Exposure to more than 4 new chemical entities within 12 months prior to dosing.
* A positive drug/alcohol test at screening or Day -1
* The participant is at high-risk of Mycobacterium tuberculosis (MTB) infection in the opinion of the Investigator.
* History of asthma, allergic rhinitis or atopic dermatitis defined by the need for intermittent or continuous therapy or any other significant allergies that, in the opinion of the investigator contraindicates their participation.
* History of severe adverse reaction to local anesthetic.
* Presence of keloids or history of keloids.
* Prothrombin time (PT) or activated partial thromboplastin time (aPTT) \>1.5x upper limit of normal (ULN) at screening.
* History or presence of excessive bleeding or coagulation disorders that in the opinion of the Investigator poses a safety risk with regards to participation in the trial.
* Presence of tattoos, naevi or other skin abnormalities on the volar forearm Fitzpatrick skin color grades V in the opinion of the investigator, interfere with study assessments
* Participating, within 7 days of dosing, in recreational sun-bathing, or use of sunbed, on the area of the skin from wrist to shoulder inclusive.
* Current smoker or user of tobacco- or nicotine-containing products (e.g. nicotine patches or vaporizing devices) during or within 30 days prior to study participation.
* An average weekly intake of \>14 units of alcohol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes